ARTICLE | Clinical News
LDP-02: Began Phase II trial
February 12, 2001 8:00 AM UTC
Millennium Pharmaceuticals Inc. (MLNM), Cambridge, Mass. Product: LDP-02 Business: Autoimmune/Inflammation Therapeutic category: Antibody, Cell adhesion Target: Integrin alpha4-beta7 on lymphocytes De...